Grifols, S.A.

Grifols SA engages in the production of plasma derivatives. It operates through the following segments: Bioscience, Hospital, Diagnostic, Bio Supplies, and Others. The Bioscience Segment includes all activities related with products deriving from human plasma for therapeutic use. The Hospital Segment comprises of all non-biological pharmaceutical products and medical supplies manufactured by group companies earmarked for hospital pharmacy. The Diagnostic Segment deals with the marketing of diagnostic testing equipment, reagents, and other equipment. The Bio Supplies segment consists of all transactions related to biological products for non-therapeutic use. The Others segment focuses on the rendering of manufacturing services to third party companies. The company was founded by José Antonio Grifols Roig on November 18, 1940 and is headquartered in Barcelona, Spain.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q4 2021

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Spanish drug maker Grifols plans to meet its debt payments in 2025 with the proceeds of new senior secured notes and the sale of its 20% stake in Shanghai RAAS to Haier Group, it said on Wednesday.

Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake

LOS ANGELES, CA / ACCESSWIRE / April 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Spanish drugmaker Grifols on Thursday issued new details of its 2022 and 2023 accounts, including higher leverage ratios than previously reported based on a different calculation of its core earnings and debt, after it was required to do so by market supervisor CNMV.

Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor

BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR), the first for an automated nucleic acid test (NAT) specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.

Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening

NEW YORK , March 27, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Grifols S.A. ("Grifols" or the "Company") (NASDAQ: GRFS).

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Grifols S.A. - GRFS

Shares in Grifols fell more than 9% on Thursday after credit rating agencies Fitch and S&P downgraded their ratings for the beleaguered Spanish drugmaker, citing lower than expected free cash flow generation and refinancing risks.

Shares in Spanish drugmaker Grifols tumble on Fitch, S&P downgrades

Shares in Spanish drugmaker Grifols fell to a 12-year low on Wednesday, following the publication of a new report by Gotham City Research questioning the financial accounts of the Barcelona-based company.

Grifols shares drop to 12-year low after new Gotham City Research report

Shares in Spanish drugmaker Grifols fell nearly 15% in early trading on Wednesday following the publication of a new report by Gotham City Research questioning the Barcelona-based company's "transparency, integrity and ethical conduct".

Grifols shares drop 15% after new Gotham City Research report

Grifols' $1.8 billion sale of a 20% stake in Shanghai RAAS will proceed after a due diligence process concluded "satisfactorily", the Spanish drug maker said on Friday.

Grifols says due diligence done, Shanghai RAAS stake sale to go ahead

Spanish drug maker Grifols' top executive Thomas Glanzmann said on Thursday he will become non-executive chairman in 2025 as part of the beleaguered company's management overhaul. Glanzmann, who is currently both chief executive and executive chairman, had said earlier this month he would leave the CEO job on April 1, but remain executive chairman afterwards.

Grifols CEO Glanzmann to become non-executive chairman in 2025

Spanish pharma group Grifols was silent on the short-selling attack from Gotham City Research in today's annual earnings call. Grifols found itself under scrutiny from US-based Gotham City earlier this month for its ties with a company called Scranton Enterprise, among other accounting irregularities.

Grifols hushed on Gotham City short-sell attack during annual results

Gotham City Research has once again questioned the Spanish pharma group Grifols' ties with a company called Scranton Enterprises. Gotham via its website has posed a series of incendiary questions, following on from its negative analysis last month.

Gotham City Research once again questions Grifols

Short seller Gotham City Research has renewed its campaign against Spanish pharmaceutical company Grifols, after its responses to Gotham's original hit piece failed to cut the mustard. Gotham's short-selling report published in January focused on Grifols' handling of debt and its relationship with Scranton Enterprises, a family-owned entity connected to Grifols.

Gotham City Research renews short-sell attack on Grifols

Short-seller fund Gotham City Research on Tuesday issued a second report on Grifols , maintaining some of its questions over the Spanish pharmaceutical company's accounting practices.

Gotham City issues new report on Grifols, maintains questions over accounting practices

Zoetis

Investors with an interest in Medical - Drugs stocks have likely encountered both Grifols (GRFS) and Zoetis (ZTS). But which of these two stocks offers value investors a better bang for their buck right now?

GRFS or ZTS: Which Is the Better Value Stock Right Now?

BARCELONA, Spain, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world's leading producers of plasma-derived medicines, today announced that Biotest's positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate (FC), BT524, advance this potential treatment for acquired fibrinogen deficiency (AFD), an underserved growth market.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

LOS ANGELES, CA / ACCESSWIRE / February 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Grifols (GRFS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Here's Why Grifols (GRFS) Is a Great 'Buy the Bottom' Stock Now

NEW YORK , Jan. 26, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially misleading business information to the investing public.

ROSEN, TOP RANKED NATIONAL INVESTOR ATTORNEYS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF

LOS ANGELES, CA / ACCESSWIRE / January 25, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Grifols, S.A. ("Grifols" or "the Company") (NASDAQ:GRFS) for violations of the securities laws.

SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Grifols, S.A. and Encourages Investors with Losses to Contact the Firm

Spanish stock market supervisor said on Tuesday it is analysing the response from drugmaker Grifols to the allegations in a report from short-seller Gotham City which questioned its financial accounts.

Spanish supervisor analysing Grifols' response to Gotham City report

Grifols will send "very, very soon" its responses to a query made by Spain's CNMV stock market supervisor, in advance of reaching a ten-day deadline that expires next week, Grifols' board member Tomas Daga told Reuters on Friday.

Grifols to respond "very, very soon", before deadline, to supervisor request - board member

Ratings agency S&P on Friday kept its 'B+' rating for Grifols , with a stable outlook for 2024, in a boost for the Spanish pharmaceutical company after a report by short-seller Gotham City Research sent its shares tumbling last week.

S&P keeps Grifols at 'B+', sees leverage decreasing in 2024

NEW YORK , Jan. 18, 2024 /PRNewswire/ --   WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Grifols, S.A. (NASDAQ: GRFS) (OTC: GIKLY, GIFOF, GIFLF) resulting from allegations that Grifols may have issued materially misleading business information to the investing public.

ROSEN, NATIONAL TRIAL LAWYERS, Encourages Grifols, S.A. Investors to Inquire About Securities Class Action Investigation - GRFS, GIKLY, GIFOF, GIFLF

The European Central Bank has asked some lenders to detail their exposure to Spain's Grifols and its related entities, after the drugmaker was last week accused of manipulating its financial accounts by a short-seller, sources said.

News for Grifols, S.A. Stock (GRFS)